Cybin (CYBN) News Today $9.09 -0.24 (-2.57%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.04 -0.04 (-0.50%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Analysts Offer Insights on Healthcare Companies: Cybin (CYBN) and Corbus Pharmaceuticals (CRBP)February 18, 2025 | markets.businessinsider.comHC Wainwright Cuts Cybin (NYSE:CYBN) Price Target to $150.00HC Wainwright cut their price target on shares of Cybin from $190.00 to $150.00 and set a "buy" rating on the stock in a research note on Thursday.February 13, 2025 | marketbeat.comCybin (NYSE:CYBN) Given New $73.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group reduced their price objective on shares of Cybin from $86.00 to $73.00 and set a "buy" rating for the company in a report on Wednesday.February 12, 2025 | marketbeat.comCybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business HighlightsFebruary 10, 2025 | businesswire.comEquities Analysts Set Expectations for Cybin Q3 EarningsCybin Inc. (NYSE:CYBN - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Cybin in a research report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.51) per share for the qJanuary 30, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for Cybin FY2029 Earnings?Cybin Inc. (NYSE:CYBN - Free Report) - Stock analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for shares of Cybin in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now forecasts that the company will post eJanuary 30, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of Cybin FY2029 EarningsCybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Cybin in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will postJanuary 29, 2025 | marketbeat.comCybin’s depression program advancing in Phase 3, says H.C. WainwrightJanuary 28, 2025 | markets.businessinsider.comCybin’s Promising Clinical Developments and Strategic Partnerships Fuel Buy Rating and $190 Price TargetJanuary 28, 2025 | markets.businessinsider.comH.C. Wainwright maintains $190 target on Cybin Inc. sharesJanuary 28, 2025 | msn.comCybin (NYSE:CYBN) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $190.00 price objective on shares of Cybin in a research note on Monday.January 27, 2025 | marketbeat.comCybin launches clinical site partnerships to support PARADIGM programJanuary 16, 2025 | markets.businessinsider.comCybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderJanuary 15, 2025 | businesswire.comCybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025January 13, 2025 | businesswire.comJane Street Group LLC Has $204,000 Stake in Cybin Inc. (NYSE:CYBN)Jane Street Group LLC lessened its stake in shares of Cybin Inc. (NYSE:CYBN - Free Report) by 84.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,003 shares of the company's stock after selling 129,272 shares during thJanuary 13, 2025 | marketbeat.comCybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025January 9, 2025 | businesswire.comCybin (NYSE:CYBN) Trading Up 1% - Time to Buy?Cybin (NYSE:CYBN) Stock Price Up 1% - Should You Buy?December 28, 2024 | marketbeat.comPEAK6 Investments LLC Trims Stock Holdings in Cybin Inc. (NYSE:CYBN)PEAK6 Investments LLC lowered its stake in shares of Cybin Inc. (NYSE:CYBN - Free Report) by 97.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,370 shares of the company's stock after selling 420,51December 6, 2024 | marketbeat.comCybin to Participate in Water Tower Research Fireside Chat on December 11, 2024December 4, 2024 | businesswire.comBloom Burton Has Negative Outlook of Cybin FY2025 EarningsCybin Inc. (NYSE:CYBN - Free Report) - Equities research analysts at Bloom Burton cut their FY2025 earnings estimates for shares of Cybin in a note issued to investors on Tuesday, November 19th. Bloom Burton analyst D. Martin now expects that the company will earn ($6.12) per share for the year,November 22, 2024 | marketbeat.comHC Wainwright Has Bearish Estimate for Cybin Q3 EarningsCybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright lowered their Q3 2025 earnings estimates for Cybin in a research note issued on Tuesday, November 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.53) for the quarNovember 21, 2024 | marketbeat.comOptimistic Buy Rating for Cybin: Promising CYB003 Phase 2 Results and Market PotentialNovember 19, 2024 | markets.businessinsider.comCybin’s CYB003: Promising Clinical Trial Results Lead to Buy RatingNovember 19, 2024 | markets.businessinsider.comCybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive DisorderNovember 18, 2024 | theglobeandmail.comCybin Stock In Focus On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely BullishNovember 18, 2024 | msn.comCybin’s CYB003: Promising Efficacy in MDD and Strong Buy Rating ReaffirmedNovember 18, 2024 | markets.businessinsider.comCybin: CYB003 data demonstres ‘breakthrough 12-month efficacy’ in MDD treatmentNovember 18, 2024 | markets.businessinsider.comCybin (NYSE:CYBN) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $190.00 price objective on shares of Cybin in a research report on Monday.November 18, 2024 | marketbeat.comCybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...November 14, 2024 | businesswire.comCanaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $86.00Canaccord Genuity Group dropped their price objective on shares of Cybin from $96.00 to $86.00 and set a "buy" rating for the company in a report on Thursday.November 14, 2024 | marketbeat.comCybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024November 14, 2024 | businesswire.comCybin (AMEX:CYBN) Stock Quotes, Forecast and News SummaryNovember 14, 2024 | benzinga.comCybin’s Phase 3 Trials and Financial UpdateNovember 13, 2024 | markets.businessinsider.comCybin launches new program phase to treat major depressive disorderNovember 13, 2024 | msn.comCybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat DepressionNovember 13, 2024 | benzinga.comCybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial ResultsNovember 13, 2024 | businesswire.comCybin Inc. (NYSE:CYBN) is Rosalind Advisors Inc.'s 6th Largest PositionRosalind Advisors Inc. trimmed its holdings in Cybin Inc. (NYSE:CYBN - Free Report) by 94.4% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,075,105 shares of the company's stock after selling 18,224,895 shares during the quarter. Cybin accounNovember 6, 2024 | marketbeat.comCybin’s Promising Growth in the Psychedelic Sector Justifies Buy RatingNovember 4, 2024 | markets.businessinsider.comPDS Planning Inc Has $2.38 Million Stock Holdings in Cybin Inc. (NYSE:CYBN)PDS Planning Inc reduced its holdings in shares of Cybin Inc. (NYSE:CYBN - Free Report) by 76.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 267,580 shares of the company's stock after selling 885,540 shares during tNovember 4, 2024 | marketbeat.comCybin to Highlight Innovations at Health SummitOctober 31, 2024 | markets.businessinsider.comCybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines ProgramOctober 24, 2024 | businesswire.comSanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN)Sanctuary Advisors LLC bought a new stake in Cybin Inc. (NYSE:CYBN - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 131,252 shares of the company's stock, valued at approximateOctober 22, 2024 | marketbeat.comCybin (NYSE:CYBN) Trading Down 7.4% - Here's What HappenedCybin (NYSE:CYBN) Stock Price Down 7.4% - Here's WhyOctober 21, 2024 | marketbeat.comCybin (NYSE:CYBN) Trading 9.7% Higher - Should You Buy?Cybin (NYSE:CYBN) Stock Price Up 9.7% - Still a Buy?October 18, 2024 | marketbeat.comCybin (NYSE:CYBN) Shares Gap Down - What's Next?Cybin (NYSE:CYBN) Shares Gap Down - Time to Sell?October 14, 2024 | marketbeat.comCybin (NYSE:CYBN) Trading Up 5.4% - Here's WhyCybin (NYSE:CYBN) Trading 5.4% Higher - Still a Buy?October 10, 2024 | marketbeat.comWater Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”September 27, 2024 | globenewswire.comStrong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management PositioningSeptember 24, 2024 | markets.businessinsider.comCybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitSeptember 24, 2024 | finance.yahoo.comCybin (NYSE:CYBN) Sees Large Volume IncreaseCybin (NYSE:CYBN) Sees Strong Trading VolumeSeptember 23, 2024 | marketbeat.com Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address CYBN Media Mentions By Week CYBN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼0.500.60▲Average Medical News Sentiment CYBN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼11▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVB News Today PRTA News Today CRON News Today GHRS News Today BCAX News Today VERV News Today MNMD News Today DNTH News Today AVXL News Today OPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CYBN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
